ThermoGenesis Holdings, Inc. (THMO)

NASDAQ: THMO · IEX Real-Time Price · USD
4.23
+0.28 (7.09%)
At close: Feb 3, 2023, 4:00 PM
4.22
-0.01 (-0.24%)
After-hours: Feb 3, 2023, 7:58 PM EST
7.09%
Market Cap 4.39M
Revenue (ttm) 10.23M
Net Income (ttm) -10.49M
Shares Out 1.04M
EPS (ttm) -30.60
PE Ratio n/a
Forward PE 2.28
Dividend n/a
Ex-Dividend Date n/a
Volume 243,082
Open 4.05
Previous Close 3.95
Day's Range 3.96 - 4.54
52-Week Range 2.67 - 40.95
Beta 2.54
Analysts Buy
Price Target 45.90 (+985.11%)
Earnings Date Mar 27, 2023

About THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automa... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1986
Employees 39
Stock Exchange NASDAQ
Ticker Symbol THMO
Full Company Profile

Financial Performance

In 2021, THMO's revenue was $9.29 million, a decrease of -4.62% compared to the previous year's $9.74 million. Losses were -$11.38 million, -30.41% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for THMO stock is "Buy." The 12-month stock price forecast is $45.9, which is an increase of 985.11% from the latest price.

Price Target
$45.9
(985.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

RANCHO CORDOVA, Calif. , Jan. 11, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

3 weeks ago - PRNewsWire

ThermoGenesis Announces 1-for-45 Reverse Stock Split

RANCHO CORDOVA, Calif. , Dec. 21, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

1 month ago - PRNewsWire

ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo...

3 months ago - Zacks Investment Research

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

3 months ago - PRNewsWire

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update

Conference  Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and poi...

3 months ago - PRNewsWire

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING

RANCHO CORDOVA, Calif. , Oct. 28, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

3 months ago - PRNewsWire

THERMOGENESIS PRICES $2.05 MILLION PUBLIC OFFERING

RANCHO CORDOVA, Calif. , Oct. 25, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

3 months ago - PRNewsWire

ThermoGenesis Holdings to Present at the H.C. Wainwright 24th Annual Global Investment Conference

RANCHO CORDOVA, Calif. , Sept. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, ...

5 months ago - PRNewsWire

ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m.

6 months ago - PRNewsWire

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update

Conference  Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and...

6 months ago - PRNewsWire

ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2022 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

9 months ago - PRNewsWire

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update

Conference  Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif. , May 18, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and se...

9 months ago - PRNewsWire

ThermoGenesis Holdings Announces Year End 2021 Financial Results and Provides Corporate Update

Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies Leases 35,475 SF To Be Built-Out as cGMP Complia...

11 months ago - PRNewsWire

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2021 and Provide a Corporate Strategic Update

Conference  Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif. , March 23, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools an...

11 months ago - PRNewsWire

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022

RANCHO CORDOVA, Calif., Jan. 11, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") will re...

1 year ago - PRNewsWire

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

RANCHO CORDOVA, Calif., Jan. 10, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, t...

1 year ago - PRNewsWire

ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders

RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thur...

1 year ago - PRNewsWire

Recap: ThermoGenesis Holdings Q3 Earnings

ThermoGenesis Holdings (NASDAQ:THMO) reported its Q3 earnings results on Friday, November 12, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

1 year ago - Benzinga

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2021, and Provides Corporate Update

RANCHO CORDOVA, Calif., Nov. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, t...

1 year ago - PRNewsWire

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif., Nov. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, to...

1 year ago - PRNewsWire

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies

RANCHO CORDOVA, Calif., Sept. 14, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, ...

1 year ago - PRNewsWire

Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

RANCHO CORDOVA, Calif., Sept. 7, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, to...

1 year ago - PRNewsWire

ThermoGenesis Holdings, Inc. (THMO) Reports Q2 Loss, Tops Revenue Estimates

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -111.11% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the...

1 year ago - Zacks Investment Research

Recap: ThermoGenesis Holdings Q2 Earnings

Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased 2.7% after the company reported Q2 results. Quarterly Results Earnings per share rose 62.75% over the past year to ($0.38), which missed the es...

1 year ago - Benzinga